Artal Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Artal Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,500	Closed	-$375K	–	113
2018 Q3	$375K	Hold	7,500	–	–	0.01%	105
2018 Q2	$383K	Hold	7,500	–	–	0.01%	104
2018 Q1	$315K	Hold	7,500	–	–	﹤0.01%	109
2017 Q4	$698K	Hold	7,500	–	–	0.01%	117
2017 Q3	$1.13M	Hold	7,500	–	–	0.02%	105
2017 Q2	$780K	Hold	7,500	–	–	0.01%	104
2017 Q1	$893K	Buy	7,500 +4,295	+134%	+$496K	0.02%	89
2016 Q4	$452K	Hold	3,205	–	–	0.01%	90
2016 Q3	$323K	Hold	3,205	–	–	0.01%	92
2016 Q2	$228K	Hold	3,205	–	–	﹤0.01%	68
2016 Q1	$296K	Buy	+3,205	New	+$284K	0.01%	58

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WJA

Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Artal Group's IMDX Position: Q4 2018 in Review

Artal Group sold out of Insight Molecular Diagnostics (IMDX) in Q4 2018, closing a stake of 7,500 shares — an estimated $375K sold.

Artal Group first reported a position in IMDX in Q1 2016 and held it in 11 quarters. The position peaked at $1.13M in Q3 2017. 22 funds tracked by Wall St. Rank hold IMDX as of Q4 2018.

Artal Group reported no remaining Insight Molecular Diagnostics position as of Q4 2018 after selling out during the quarter.
Artal Group sold 7,500 Insight Molecular Diagnostics shares in Q4 2018, an estimated $375K.
Artal Group first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 11 quarters.
Artal Group's Insight Molecular Diagnostics position peaked at $1.13M in Q3 2017.
22 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2018.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.